Combination Pricing Solution As Elusive As Ever
Executive Summary
The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.
You may also be interested in...
Better Data Tracking Could Hold Key To Indication-Based Pricing Progress
Indication-based pricing could become a reality with better infrastructure to track utilization data.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.